Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing
Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.
The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.
Spike in PSA level after starting abiraterone does not affect progression-free or overall survival, study finds.
Also increased risk of progression to metastatic disease compared with the general population.
The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.
Pathologic Gleason scores, positive surgical margin rates, and PSA doubling times differentiate earlier from later biochemical recurrence after radical surgery.
In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.